Real-world data on stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area (PACIFIC AA)

Trial Identifier: D4194R00023
Sponsor: AstraZeneca
NCTID:: NCT04529564
Start Date: June 2020
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Taiwan Hsinchu, Taiwan
Taiwan Kaohsiung, Taiwan
Taiwan Keelung, Taiwan
Taiwan Taichung, Taiwan
Taiwan Tainan, Taiwan
Taiwan Taipei, Taiwan
Taiwan Taoyuan, Taiwan